Phenibut-Akrikhin
Phenibut-Akrikhin: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Use in the elderly
- 14. Drug interactions
- 15. Analogs
- 16. Terms and conditions of storage
- 17. Terms of dispensing from pharmacies
- 18. Reviews Phenibute-Akrihin
- 19. Price in pharmacies
Latin name: Phenybut-Akrihin
ATX code: N06BX22
Active ingredient: aminophenylbutyric acid (Aminophenylbutyric acid)
Producer: JSC "Chemical and pharmaceutical plant" Akrikhin "(Russia)
Description and photo update: 2020-10-03
Phenibut-Akrikhin is a nootropic drug with anxiolytic activity.
Release form and composition
Dosage form of the drug - tablets: round, flat-cylindrical, with a chamfer, on one side there is a dividing line, from pure white to yellowish-white color (10 pcs. In a package of a cellular contour made of polyvinyl chloride film and aluminum foil; in a pack of cardboard, 2 packages and instructions for use of Phenibut-Akrihin).
Composition for 1 tablet:
- active ingredient: phenibut (aminophenylbutyric acid hydrochloride) - 250 mg;
- auxiliary ingredients: MCC (microcrystalline cellulose), potato starch, polyvinylpyrrolidone K30, calcium stearate.
Pharmacological properties
Pharmacodynamics
Phenibut-Akrikhin is a nootropic agent, the active ingredient of which is aminophenylbutyric acid hydrochloride (phenibut), a derivative of phenylethylamine and GABA (gamma-aminobutyric acid). The drug supports the GABA-mediated transmission of nerve impulses in the CNS (central nervous system) by directly acting on the GABA receptors. In addition, it has antiplatelet, psychostimulating, tranquilizing and antioxidant effects.
Pharmacological properties of Phenibut:
- improving the functional state of the brain by normalizing tissue metabolism and stimulating blood circulation by increasing the volumetric and linear velocity of cerebral blood flow, reducing the tone of cerebral vessels, increasing microcirculation and antiplatelet action;
- decrease or complete loss of feelings of anxiety, worry, tension, fear; anticonvulsant efficacy;
- prolongation of the latent period and reduction in the duration and severity of nystagmus; improvement of microcirculation in the tissues of the eye;
- relief of manifestations of asthenia and vasovegetative symptoms (including headache, a feeling of heaviness in the head, sleep disturbances, irritability, emotional lability);
- improvement of the following psychological indicators: attention, accuracy and speed of sensory-motor reactions;
- increase in physical and mental performance, improvement of memory, normalization of sleep, improvement of the condition of patients with motor and speech pathologies - as a result of the course;
- improvement of well-being, motivation of activity in the form of increased interest in life, manifestation of initiative (without sedation or excitement) - from the first days of therapy for patients with asthenia;
- an increase in the number of mitochondria in perifocal areas, an improvement in the course of bioenergetic processes in the tissues of the brain - when used after severe traumatic brain injury (TBI);
- restoration of lipid peroxidation processes in the case of neurogenic lesions of the heart and stomach;
- reducing the depressing effect of ethanol on the central nervous system.
Phenibut is low-toxic, has no effect on choline and adrenergic receptors.
In old age, Phenibut-Akrikhin does not cause excessive lethargy or congestion, while the relaxing effect of the drug is most often absent.
Pharmacokinetics
After oral administration, Phenibut is well absorbed and penetrates into all organs and tissues of the body. About 0.1% of aminophenylbutyric acid hydrochloride penetrates into the brain from the dose taken. An increase in the permeability of the blood-brain barrier is possible in young and elderly patients.
3 hours after taking the tablet, the substance is found in the urine. At the same time, its concentration in the brain tissues remains unchanged, where phenibut is determined after another 6 hours.
Phenibut metabolism occurs in the liver (80–95%) with the formation of pharmacologically inactive metabolites.
Up to 5% of the substance unchanged undergoes renal elimination. 24 hours after taking Phenibut, it can only be detected in urine. 48 hours after ingestion, about 5% of the dose taken is found in the urine. The greatest binding occurs in the liver (at 80%), but it is not specific.
Repeated intake of Phenibut-Akrikhin does not lead to the accumulation of the substance in the body.
Indications for use
- asthenic syndrome, anxiety and neurotic states;
- enuresis, stuttering, tics in children;
- night anxiety, insomnia in elderly patients;
- Morbus Meniere (Meniere's disease);
- dizziness caused by dysfunction of the vestibular analyzer of various etiologies;
- kinetosis (sea, automobile, air and other similar diseases) - for the prevention of motion sickness;
- alcohol withdrawal syndrome - as part of a combination treatment for the relief of somatovegetative and psychopathological disorders.
Contraindications
Absolute:
- renal failure in the acute phase;
- period of pregnancy;
- breast-feeding;
- children under 3 years old;
- rare congenital galactose intolerance, lactase deficiency or glucose-galactose malabsorption (the tablets contain lactose);
- established individual hypersensitivity to aminophenylbutyric acid or auxiliary ingredients of the drug.
Phenibut-Akrikhin should be taken with caution in case of erosive and ulcerative diseases of the gastrointestinal tract, due to the irritating effect of the agent, it is recommended to prescribe it in smaller doses.
Phenibut-Akrikhin, instructions for use: method and dosage
Phenibut-Akrikhin tablets are intended for oral administration. They are taken regardless of the patient's regimen and diet.
The dose, frequency of administration and duration of the course of therapy are determined by the attending physician, depending on the age of the patient, the clinical picture of the disease, and the tolerability of the drug.
The recommended dosage regimen of Phenibut-Akrikhin, due to the indications:
- asthenic syndrome, anxiety and neurotic states (children over 14 years old and adult patients): 1-2 tablets of Phenibut-Akrikhin (250-500 mg of Phenibut) 3 times a day. The maximum single dose for adults is 3 tablets (750 mg), for patients over 60 years old - 2 tablets (500 mg). If necessary, the daily dose may be increased to a maximum of 10 tablets (2500 mg). The course of treatment is from 4 to 6 weeks;
- asthenic syndrome, anxiety-neurotic states (pediatric patients): with a frequency of administration 2-3 times a day at the age of 3-8 years, a single dose is 0.5 tablets (125 mg), at the age of 8-14 years - 1 tablet (250 mg). The course of treatment is from 4 to 6 weeks;
- enuresis, stuttering, tics: a single dose in children aged 3–8 years is 0.5 tablets (125 mg), at the age of 8–14 years - 1 tablet (250 mg), the frequency of administration is 2-3 times a day; children over 14 years of age are recommended doses for adult patients;
- night anxiety, insomnia in elderly patients: single dose of Phenibut-Akrikhin - 1-2 tablets (250-500 mg), frequency of administration - 3 times a day;
- dizziness caused by dysfunction of the vestibular analyzer of an infectious nature (otogenic labyrinthitis) and Meniere's disease: to eliminate dizziness during an exacerbation - 3 tablets (750 mg) 3 times a day, course - 5-7 days; after a decrease in the severity of vestibular disorders - 1-2 tablets (250-500 mg) 3 times a day, the course is 5-7 days; then 1 tablet (250 mg) 1 time per day for 5 days. Relatively mild course of the disease - 1 tablet (250 mg) 2 times a day, course - 5-7 days; then 1 tablet (250 mg) once a day for 7-10 days;
- dizziness caused by dysfunction of the vestibular analyzer of vascular and traumatic genesis: to eliminate dizziness - 1 tablet of Phenibut-Akrihin (250 mg) 3 times a day, course - 12 days;
- kinetosis (sea, automobile, air and other similar diseases): for the prevention of motion sickness 1 hour before the planned trip or in the case of the first symptoms of motion sickness, take 1-2 tablets (250-500 mg) once. The anti-pumping effect of phenibut increases with increasing doses. But with indomitable vomiting and other pronounced manifestations of motion sickness, Phenibut-Akrikhin is ineffective even when taken in a single dose of 3-4 tablets (750-1000 mg);
- alcohol withdrawal syndrome (as part of a combination treatment) in order to relieve somatovegetative and psychopathological disorders: in the first days - 1-2 tablets (250-500 mg) 3 times throughout the day and 3 tablets (750 mg) before going to bed at night. The daily dose is gradually reduced to the usual for adult patients.
In case of renal / hepatic insufficiency, prolonged use of Phenibut-Akrikhin must be accompanied by monitoring of renal / liver function indicators.
Side effects
Phenibut-Akrikhin, like other medicines, can cause negative side reactions. Usually they do not appear in all patients, since the drug is generally well tolerated.
Possible side effects of Phenibut-Akrikhin on the part of systems and organs:
- CNS: drowsiness, increased symptoms of the disease (at the beginning of therapy), headache, dizziness;
- gastrointestinal tract: nausea (at the beginning of therapy);
- skin and subcutaneous fat: dermatological reactions (itching, skin rash);
- hepatobiliary system: hepatotoxicity (with prolonged use of high doses).
Overdose
Phenibut is low toxic. Overdose episodes were not reported.
Symptoms of intoxication can be nausea, vomiting, drowsiness, dizziness. Long-term use of the drug in high doses can cause the development of eosinophilia, arterial hypotension, renal dysfunction, liver lipodystrophy (in the case of taking more than 7000 mg).
For the purpose of therapy, it is recommended to wash the stomach, after which, if necessary, prescribe symptomatic treatment to maintain the vital functions of the body.
Phenibut has no specific antidote.
special instructions
Long-term use of Phenibut-Akrikhin (more than 2-3 weeks) requires monitoring the parameters of peripheral blood and liver function once every 2-3 weeks.
Influence on the ability to drive vehicles and complex mechanisms
Due to the fact that in some patients Phenibut-Akrikhin can cause such disorders from the central nervous system as drowsiness and dizziness, during therapy, care should be taken when driving vehicles and engaging in other potentially hazardous types of work that require increased concentration of attention and high speed of psychomotor reactions.
Application during pregnancy and lactation
Pregnant and breastfeeding women are not recommended to take Phenibut-Akrikhin tablets, since there is insufficient clinical experience.
In experimental studies on animals, the mutagenic, teratogenic and embryotoxic effects of the drug have not been established.
Pediatric use
In pediatric practice, the use of Phenibut-Akrihin is contraindicated for the treatment of children under 3 years of age.
With impaired renal function
Patients with renal insufficiency with long-term use of Phenibut-Akrikhin require monitoring of renal function indicators.
For violations of liver function
Patients with hepatic impairment with long-term use of phenibut require monitoring of liver function indicators.
In patients with impaired liver function, taking high doses of Phenibut-Akrikhin can cause hepatotoxicity, and therefore it is recommended to prescribe the minimum effective dose.
Use in the elderly
Elderly patients do not need to adjust the Phenibut dosage regimen.
Drug interactions
Taking aminophenylbutyric acid with other psychotropic drugs can cause synergy of action, which will mutually reduce their doses.
Phenibut-Akrikhin prolongs and potentiates the effect of neuroleptic, hypnotic, antiparkinsonian, anticonvulsant drugs.
Analogs
The analogues of Phenibut-Akrihin are Anvifen, Glycine-Bio Pharmaplant, Bifren, Gliatilin, Noobut IC, Noofen, Nootropil, Quattrex, Phenibut, Phenibut-LekT, etc.
Terms and conditions of storage
Store at temperatures up to 25 ° C in a dry place. Keep out of the reach of children.
Shelf life is 2 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Phenibut-Akrihin
The use of the drug for the treatment of both adult patients and children is quite effective, so everyone leaves only positive reviews about Phenibut-Akrihin. The drug is well tolerated, begins to act from the moment it is taken, does not cause strong side reactions and addiction, is available in most pharmacies, and is inexpensive.
In some cases, they mention discomfort in the stomach immediately after swallowing the pill and irritability when skipping the next dose. The disadvantages also include the Phenibut-Akrihin vacation only with a doctor's prescription.
Price for Phenibut-Akrikhin in pharmacies
Estimated price for Phenibut-Akrikhin, tablets of 250 mg, for 20 pcs. in the package is about 180 rubles.
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
